TNF and rheumatoid arthritis: Indeed, an evidence of no difference in efficacy of ETN in monotherapy vs combination therapy with csDMARDs was demonstrated, while both ADA and IFX demonstrated that co-medication with csDMARDs provides an additional advantage over anti-TNF monotherapy, in terms of either retention or DAS28 remission rate in RA (107).